Home
Storia in 1 fonti
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer
POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance
Raccontata da
medpagetoday.com
Timeline cronologica
- ·
Durvalumab Plus BCG Cut Early Recurrence of High-Risk Bladder Cancer
POTOMAC data support a year's worth of immuontherapy paired with BCG induction and maintenance
- ·
Half of Patients With Post-BCG Bladder Cancer Achieve CR With Nonviral Gene Therapy
Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety
- ·
Major Complete Response Rate in Very High-Risk Bladder Cancer With Combo Treatment
Only three of 37 patients did not achieve CR at 6 months with pembrolizumab and BCG